Pensacola, FL Â- ActiGraph, a leading provider of wearable activity and sleep measurement solutions for the global pharmaceutical industry and academic research community, has announced the upcoming launch of the CentrePoint Data Hub, a homeÂbased communication gateway that securely transmits data captured by ActiGraph activity monitors and other connected health devices to the CentrePoint cloud software platform via cellular network. The CentrePoint Data Hub is an extension of ActiGraph’s CentrePoint platform, a webÂbased technology suite used to deploy and manage activity monitor data collection within clinical development and health research environments. The CentrePoint Data Hub provides a simple, flexible way for clinical trial and research study participants to share their physical activity and sleep information with the study team from the comfort of home, without the need for a PC or smartphone. The plugÂandÂplay CentrePoint Data Hub syncs with ActiGraph activity monitors using USB 2.0 or Bluetooth LE, and collected data is seamlessly uploaded to the CentrePoint system via 3G cellular network. Participant data is immediately accessible through the CentrePoint web portal, providing the research team with an opportunity to quickly intervene if costly and timeÂconsuming noncompliance issues arise. RealÂtime participant measures can also be used to inform earlier clinical decision making and support adaptive trial designs. “The CentrePoint Data Hub was developed with two specific goals in mind,” said Jeremy Wyatt, ActiGraph CTO and Senior Vice President of Product Development. “We set out to build a solution that provides our pharma and research clients with actionable, realÂtime information that has the potential to impact the success of a trial. Secondly, and just as important, our solution had to be practically effortless on the part of the participants, who may already be burdened with numerous other tests and procedures.” “We see a lot of interest from pharmaceutical clinical trial sponsors in capturing objective activity and sleep information from clinical trial patients in real time,” said James Munz, Vice President of Innovation at ERT. “This is exactly the type of solution we are exploring in our Innovation Lab â one that offers the potential for pharmaceutical companies and clinical research organizations to improve clinical trial data collection through the use of validated mHealth devices during new medical product development.” About ActiGraph ActiGraph’s extensively validated suite of hardware and software products are widely used by prominent scientific, academic, and pharmaceutical organizations in more than 75 countries in research studies and clinical trials involving physical activity, sedentary behavior, energy expenditure, and sleep/wake behavior. ActiGraph measurement solutions have delivered objective activity and sleep measures to many high profile population studies including the National Health and Nutrition Examination Survey (NHANES), the Harvard Women’s Health Study, the German National Cohort, and the U.K. Millennium Cohort Study.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.